Literature DB >> 6695378

A comparison of the lung adenoma response in strain A/J mice after intraperitoneal and oral administration of carcinogens.

G D Stoner, E A Greisiger, H A Schut, M A Pereira, T R Loeb, J E Klaunig, D G Branstetter.   

Abstract

This study was undertaken to compare the ability of a series of compounds from different chemical classes to induce lung tumors in strain A/J mice after either ip or po administration. 3-Methylcholanthrene, benzo(a)pyrene, urethan, diethylnitrosamine, ethylnitrosourea, and dimethylhydrazine induced a significant (p less than 0.05; t test) increase in the lung tumor response when given both ip and po. 2,4-Dinitrotoluene, 2,6-dinitrotoluene, and a 2:1 mixture of 2,4-dinitrotoluene and 2,6-dinitrotoluene were inactive by both routes of administration and at all dose levels. The lung tumor response to all doses of 3-methylcholanthrene and benzo(a)pyrene, the highest dose of diethylnitrosamine, and the middle doses of both ethylnitrosourea and dimethylhydrazine varied as a function of the route of administration. This finding was most evident for the polycyclic hydrocarbons, e.g., the average number of lung tumors per mouse in animals that received the middle dose of 3-methylcholanthrene or the highest dose of benzo(a)pyrene by the ip route exceeded that by the po route by factors of 12 and 13, respectively. Tissue distribution and elimination studies were conducted in an effort to determine the basis for the observed difference in lung tumor response to 3-methylcholanthrene after ip or po administration. The data indicated that 3-methylcholanthrene persists for longer periods in the animals when given ip, thus potentially providing an extended carcinogenic stimulus. Extrapulmonary lesions observed at a higher than normal frequency at necropsy included peritoneal sarcomas (in 3-methylcholanthrene-treated mice), and both squamous cell carcinomas of the forestomach and abnormal lesions of the liver (in diethylnitrosamine-treated mice).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6695378     DOI: 10.1016/0041-008x(84)90316-8

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  7 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  High-resolution X-ray microtomography for the detection of lung tumors in living mice.

Authors:  Nora M De Clerck; Kris Meurrens; Horst Weiler; Dirk Van Dyck; Greet Van Houtte; Piter Terpstra; Andrei A Postnov
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

3.  Assignment of a locus for mouse lung tumor susceptibility to proximal chromosome 19.

Authors:  T R Devereux; R W Wiseman; N Kaplan; S Garren; J F Foley; C M White; C Anna; M A Watson; A Patel; S Jarchow
Journal:  Mamm Genome       Date:  1994-12       Impact factor: 2.957

4.  Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse.

Authors:  M You; U Candrian; R R Maronpot; G D Stoner; M W Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

5.  Subchronic oral exposure to benzo(a)pyrene leads to distinct transcriptomic changes in the lungs that are related to carcinogenesis.

Authors:  Sarah Labib; Carole Yauk; Andrew Williams; Volker M Arlt; David H Phillips; Paul A White; Sabina Halappanavar
Journal:  Toxicol Sci       Date:  2012-05-18       Impact factor: 4.849

6.  To BaP or not to BaP? That is the question.

Authors:  L S Goldstein
Journal:  Environ Health Perspect       Date:  2001-08       Impact factor: 9.031

Review 7.  Preclinical Murine Models for Lung Cancer: Clinical Trial Applications.

Authors:  Amelia Kellar; Cay Egan; Don Morris
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.